
    
      A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week
      study to evaluate the safety, efficacy and tolerability of switching from a 200mg
      ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily,
      100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)
    
  